CVS or DHR: Which Is the Better Value Stock Right Now?
Werte in diesem Artikel
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.Currently, CVS Health has a Zacks Rank of #2 (Buy), while Danaher has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that CVS has an improving earnings outlook. However, value investors will care about much more than just this.Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.CVS currently has a forward P/E ratio of 9.98, while DHR has a forward P/E of 23.97. We also note that CVS has a PEG ratio of 0.87. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. DHR currently has a PEG ratio of 2.54.Another notable valuation metric for CVS is its P/B ratio of 1. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, DHR has a P/B of 2.60.These are just a few of the metrics contributing to CVS's Value grade of A and DHR's Value grade of D.CVS is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that CVS is likely the superior value option right now.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf CVS Health
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CVS Health
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu CVS Health Corp
Analysen zu CVS Health Corp
Datum | Rating | Analyst | |
---|---|---|---|
05.06.2019 | CVS Health Buy | Standpoint Research | |
15.04.2019 | CVS Health Perform | Oppenheimer & Co. Inc. | |
12.04.2019 | CVS Health Market Perform | BMO Capital Markets | |
18.12.2018 | CVS Health Overweight | Barclays Capital | |
26.10.2018 | CVS Health Peer Perform | Wolfe Research |
Datum | Rating | Analyst | |
---|---|---|---|
05.06.2019 | CVS Health Buy | Standpoint Research | |
12.04.2019 | CVS Health Market Perform | BMO Capital Markets | |
18.12.2018 | CVS Health Overweight | Barclays Capital | |
30.01.2018 | CVS Health Strong Buy | Needham & Company, LLC | |
02.01.2018 | CVS Health Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
15.04.2019 | CVS Health Perform | Oppenheimer & Co. Inc. | |
26.10.2018 | CVS Health Peer Perform | Wolfe Research | |
28.06.2017 | CVS Health Hold | Needham & Company, LLC | |
02.02.2017 | CVS Health Neutral | Robert W. Baird & Co. Incorporated | |
22.06.2016 | CVS Health Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
25.07.2005 | Update Longs Drug Stores Corp.: Underperform | Bear Stearns |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen